

TX CLINICAL CRITERIA & PROCEDURE

CRITERIA NAME: Exagamglogene autotemcel (Casgevy®)	CRITERIA ID: TX.CC.PHAR.44
BUSINESS UNIT: Superior HealthPlan	FUNCTIONAL AREA: Pharmacy
EFFECTIVE DATE: January 1, 2025	PRODUCT(S): STAR, STAR PLUS, STAR HEALTH, STAR KIDS, CHIP, CHIP Perinate
REVIEWED/REVISED DATE:	
REGULATOR MOST RECENT APPROVAL DATE(S): N/A	

CRITERIA STATEMENT:

The purpose of this clinical criteria is to provide a guide to medical necessity reviews for exagamglogene autotemcel (Casgevy®)

PURPOSE:

Consistent with the regulation at 42 CFR Section 438.210 and 42 CFR Section 457.1230(d), services covered under managed care contracts, including clinician-administered drugs, must be furnished in an amount, duration, and scope that is no less than the amount, duration, and scope for the same services specified in the state plan. While MCOs may place appropriate limits on drugs, MCOs may not use a standard for determining medical necessity that is more restrictive than what is used in the state plan, i.e., developed by the Vendor Drug Program. For example, if a member is denied a clinician administered drug in managed care because of the MCO's prior authorization criteria but would have received the drug under the criteria specified in the state plan, then the MCO's prior authorization criteria would violate the amount, duration, and scope requirements cited above. HHSC intends to amend the Managed Care Contracts at the next opportunity to include this requirement. This same standard applies to CHIP formulary and CAD coverage.

Refer to the Outpatient Drug Services Handbook of the Texas Medicaid Provider Procedure Manual for more details on the clinical criteria and prior authorization requirements.

This medication is a non-risk based (NRB) payment drug and should follow state guidance for medical necessity review for Medicaid/CHIP due to the manner in which it is reimbursed. All determinations will be performed by a Medical Director. A pharmacy clinician will review the prior authorization request and make a recommendation to the Medical Director but will not make the ultimate determination on any case.

Additionally, this medication is a Precision Drug. Centene's Precision Drug Action Committee (PDAC) creates a standardized approach for Centene to manage precision drugs and the associated costs for their administration, prior to members presenting with a request for one of these agents. All precision drug requests or potential requests must be reported to the PDAC for tracking, regardless of whether agents are carved out, passed through, etc. All precision drug medical necessity determinations will be supported by PDAC UM recommendation, utilizing specialist input as directed and allowed by turnaround times.

The procedure code J3392 (used for Casgevy) will be limited to once per lifetime, by any provider. If the code is updated in the future it will still be limited to once per lifetime.

SCOPE:

This criteria applies to all directors, officers, and employees of Centene Corporation, its affiliates, health plans, and subsidiary companies (collectively, the "Company").

DEFINITIONS:

PDAC = Precision Drug Action Committee
 NRB = Non-Risk Based
 UM = Utilization Management
 CPS = Centene Pharmacy Services
 SHP = Superior HealthPlan

POLICY:

It is the policy of Superior HealthPlan and Centene Pharmacy Services to follow state guidance for medical necessity review of exagamglogene autotemcel (Casgevy®); procedure code: J3392.

Description/Mechanism of Action:

Exagamglogene autotemcel (Casgevy®) is an autologous genome edited hematopoietic stem cell-based gene therapy.

FDA Approved Indications:

Exagamglogene autotemcel (Casgevy®) is indicated for the treatment of clients 12 years of age and older with the following:

- Sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs); or
- Transfusion-dependent β-thalassemia (TDT).

PROCEDURE:

Provider must submit documentation (which may include office chart notes and lab results) supporting that member has met all approval criteria.

I. Initial Approval Criteria:

A. Sickle Cell Disease (SCD):

1. A Medical Director is required to review and approve or deny all requests. A pharmacy clinician will make a recommendation on the prior authorization, but ultimate determination will be made by the Medical Director only.
2. Medical necessity determinations will be supported by PDAC UM recommendation. The pharmacy clinician will review the UM recommendation with the prior authorization request for clinical appropriateness and make a recommendation to the Medical Director but will not make the ultimate determination on any case.
3. The client is 12 years of age or older.
4. The client has a diagnosis of sickle cell disease (SCD) as confirmed by genetic testing with recurrent vaso-occlusive crises (VOC), with at least two VOC events per year in the past 2 years.

Diagnosis Codes:							
D5700	D5701	D5702	D5703	D5704	D5709	D571	D5720
D57211	D57212	D57213	D57214	D57218	D57219	D5740	D57411
D57412	D57413	D57414	D57418	D57419	D5742	D57431	D57432
D57433	D57434	D57438	D57439	D5744	D57451	D57452	D57453
D57454	D57458	D57459	D5780	D57811	D57812	D57813	D57814
D57818	D57819						

5. The client has inadequate response to hydroxyurea or Adakveo (crizanlizumab).
6. Documentation that the client has not previously received allogeneic or autologous hematopoietic stem cell transplantation and does not have a matched related donor to participate in an allogenic stem hematopoietic stem cell transplant (HSCT).
7. The client has not previously received Casgevy or any other gene therapy.
8. The client has a confirmed negative serum pregnancy test.
9. The client does not have active HIV-1, HIV-2, HBV or HCV.
10. The client does not have advanced liver or chronic kidney disease.
11. Prescriber attestation is required to all of the following:
 - Discontinuation of hydroxyurea at least 8 weeks prior to mobilization and conditioning;
 - Discontinuation of Adakveo at least 8 weeks prior to mobilization and conditioning;
 - Discontinuation of iron chelators at least 7 days prior to initiation of myeloablative conditioning.
12. Prescriber attestation to monitoring of the following parameters for clients receiving Casgevy:
 - Monitor for bleeding and conduct frequent platelet counts until platelet engraftment and platelet recovery are achieved.
 - Monitor absolute neutrophil counts until engraftment has been achieved.

Approval duration: Only 1 dose per lifetime will be provided on this drug regardless of provider.

B. Transfusion-dependent β-thalassemia (TDT):

1. A Medical Director is required to review and approve or deny all requests. A pharmacy clinician will make a recommendation on the prior authorization, but ultimate determination will be made by the Medical Director only.
2. Medical necessity determinations will be supported by PDAC UM recommendation. The pharmacy clinician will review the UM recommendation with the prior authorization request for clinical appropriateness and make a recommendation to the Medical Director but will not make the ultimate determination on any case.
3. The client is 12 years of age or older.
4. The client has a diagnosis of transfusion-dependent β-thalassemia as confirmed by genetic testing (diagnosis codes D561 and D565).
5. The client has a history requiring at least 100mL/kg/year or 10 units/year of red blood cell (RBC) transfusions in the past 24 months.
6. Documentation that the client has not previously received allogeneic or autologous hematopoietic stem cell transplantation and does not have a matched related donor to participate in an allogenic stem hematopoietic stem cell transplant (HSCT).
7. The client has not previously received Casgevy or any other gene therapy.
8. The client has a confirmed negative serum pregnancy test.
9. The client does not have active HIV-1, HIV-2, HBV or HCV.
10. The client does not have advanced liver or chronic kidney disease.
11. Prescriber attestation to the discontinuation of iron chelators at least 7 days prior to initiation of myeloablative conditioning.
12. Prescriber attestation to monitoring of the following parameters for clients receiving Casgevy:
 - Monitor for bleeding and conduct frequent platelet counts until platelet engraftment and platelet recovery are achieved.
 - Monitor absolute neutrophil counts until engraftment has been achieved.

Approval duration: Only 1 dose per lifetime will be provided on this drug regardless of provider.

REFERENCES:

Texas Medicaid Provider Procedures Manual: Outpatient Drug Services Handbook

ATTACHMENTS: N/A

REVISION LOG

REVISION TYPE	REVISION SUMMARY	DATE APPROVED & PUBLISHED
New Criteria Document	N/A	01/01/2025

©2024 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.